NeoImmuneTech (XKRX:950220) Total Stockholders Equity : ₩74,856.37 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Total Stockholders Equity?

NeoImmuneTech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩74,856.37 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. NeoImmuneTech's Book Value per Share for the quarter that ended in Dec. 2023 was ₩3,785.69. The ratio of a company's debt over equity can be used to measure how leveraged this company is. NeoImmuneTech's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.05.

NeoImmuneTech Total Stockholders Equity Historical Data

The historical data trend for NeoImmuneTech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Total Stockholders Equity Chart

NeoImmuneTech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

115,885.82

84,226.68

162,042.43

119,689.26

74,856.37

NeoImmuneTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial											119,689.26	113,116.15	98,789.50	88,594.06	74,856.37

NeoImmuneTech (XKRX:950220) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

NeoImmuneTech's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(74856.372	-	0)	/	19.7735
	=	3,785.69

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

NeoImmuneTech's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1352.622	+	2555.296)	/	74856.372
	=	0.05

NeoImmuneTech Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoImmuneTech (XKRX:950220) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850

Website

http://www.neoimmunetech.com

NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines